| Name | Title | Contact Details |
|---|
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
AC Immune SA, a global leader in developing precision medicine for neurodegenerative diseases (incl. Alzheimer & Parkinsons) with cutting-edge technology platforms
Gemin
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. The company name, VenatoRx (ven-a-TOR-ex), derives from the latin word “venator”, meaning hunter and “Rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of the company. Located northwest of Philadelphia in Malvern, PA, the company was founded in 2010 by Drs. Burns, Xerri, and Pevear. Since founding, the company has received multiple awards from the NIH, including 5 Small Business Innovative Research (SBIR) grants and an R01 grant. The company has also been awarded a contract from the NIH and funding from the Wellcome Trust to advance the company’s product candidates.